CIK 0000875320
- Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- Operating
- EIN
- 043039129
- Phone
- +1 617-341-6393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,307,135
- in 1 filing, $6.3M under 10b5-1 plans
Net −$6,307,135. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-01 | Schneider Jennifer Director | Grant or award | +796 | 1,718 | ||
| 2025-05-01 | SACHS BRUCE I Director | Grant or award · Stock Option (Right to Buy) | +2,398 | 2,398 | ||
| 2025-05-01 | MCKENZIE DIANA Director | Grant or award | +796 | 3,232 | ||
| 2025-05-01 | MCKENZIE DIANA Director | Returned to the company | −1,001 | 2,231 | ||
| 2025-05-01 | MCKENZIE DIANA Director | Grant or award · Deferred Stock Units | +1,001 | 6,991.48 | ||
| 2025-05-01 | Lagarde Michel Director | Grant or award · Stock Option (Right to Buy) | +2,398 | 2,398 | ||
| 2025-05-01 | Garber Alan M Director | Grant or award | +398 | 6,872 | ||
| 2025-05-01 | Garber Alan M Director | Grant or award · Stock Option (Right to Buy) | +1,199 | 1,199 | ||
| 2025-05-01 | CARNEY LLOYD Director | Grant or award | +796 | 7,115 | ||
| 2025-05-01 | Bhatia Sangeeta N. Director | Grant or award 10b5-1 | +796 | 5,231 | ||
| 2025-04-15 | Upadhyay Suketu Director | Grant or award · Deferred Stock Units | +71.61 | $497.51 | $36K | 1,474.6 |
| 2025-04-15 | SACHS BRUCE I Director | Grant or award · Deferred Stock Units | +95.48 | $497.51 | $47K | 15,240.46 |
| 2025-03-13 | ALTSHULER DAVID EVP, Chief Scientific Officer | Sale 10b5-1 | −3,231 | $510.00 | $1.6M | 23,281 |
| 2025-03-10 | WAGNER CHARLES F JR EVP & Chief Financial Officer | Sale 10b5-1 | −3,298 | $500.00 | $1.6M | 51,671 |
| 2025-03-10 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale 10b5-1 | −3,242 | $499.99 | $1.6M | 51,239 |
| 2025-03-10 | ALTSHULER DAVID EVP, Chief Scientific Officer | Sale 10b5-1 | −3,231 | $500.00 | $1.6M | 26,512 |
| 2025-03-04 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale 10b5-1 | −4,058 | $485.49 | $2.0M | 54,481 |
| 2025-03-03 | ALTSHULER DAVID EVP, Chief Scientific Officer | Sale 10b5-1 | −3,231 | $490.00 | $1.6M | 29,743 |
| 2025-02-27 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale 10b5-1 | −530 | $475.34 | $252K | 58,539 |
| 2025-02-27 | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Sale 10b5-1 | −2,650 | $475.34 | $1.3M | 19,352 |
Page 13 of 18 · 344 trades